CoorsTek Bioceramics Wins Landmark Trademark Dispute, Ensuring Diverse Supply for Medical Devices

The U.S. Court of Appeals for the Federal Circuit has ruled in favor of CoorsTek Bioceramics in a pivotal trademark dispute, affirming the company's right to market its Permallon® Tru ceramic hip components in the United States. This decision not only represents a significant legal victory for CoorsTek but also ensures diverse supply options for critical medical devices, potentially benefiting patients worldwide.

The court's ruling upholds a 2022 decision by the U.S. Patent and Trademark Office's Trademark Trial and Appeal Board (TTAB) to cancel Ceramtec GmbH's trademark registrations related to the pink color of ceramic hip components. The dispute, initiated by CoorsTek in 2014, centered around Ceramtec's attempts to enforce trademark and trade dress claims on the pink coloration, which CoorsTek argued was a natural byproduct of the chromium oxide additive used to enhance material performance.

Jonathan Coors, CEO of CoorsTek, highlighted the broader implications of the decision, emphasizing the necessity of alternative sourcing to prevent supply shortages in the critical care market. Lucian Strong, President of CoorsTek Bioceramics, reiterated the company's commitment to innovation and quality, noting the exceptional performance and durability of Permallon® Tru products.

This legal victory opens the door for increased competition and innovation in the medical device industry, particularly in hip arthroplasty. By allowing multiple manufacturers to produce pink ceramic hip components, the decision could lead to improved availability, potentially lower costs, and greater choice for healthcare providers and patients. Furthermore, the ruling underscores the importance of prioritizing functional aspects over aesthetic trademark claims in the medical device industry, setting a precedent for future cases.

CoorsTek's Permallon® Tru hip components have already seen widespread adoption in global markets, including the United States, Korea, China, and the European Union. The Court of Appeals' decision is expected to further facilitate access to these critical medical devices, reinforcing CoorsTek's position in the bioceramics market and its century-long legacy of innovation in technical ceramics.